Avidity Biosciences, INC 8-K filings

Avidity Biosciences has priced a public offering of 10,550,000 shares of common stock at $38.00 per share, expecting gross proceeds of $400.9 million.

Avidity Biosciences reported significant reductions in DUX4 regulated genes and positive trends in functional improvements in its Phase 1/2 trial for FSHD, while also increasing the number of shares available under its incentive plan.

Avidity Biosciences has appointed Simona Skerjanec, a seasoned pharmaceutical executive, to its Board of Directors, effective May 14, 2024.

Avidity Biosciences announced its first quarter 2024 financial results, highlighted by a strong cash position and progress in clinical trials for its RNA therapeutics.

Avidity Biosciences reported positive long-term data from the MARINA-OLE trial showing reversal of disease progression in patients with myotonic dystrophy type 1 (DM1) and announced plans to initiate a Phase 3 trial in the second quarter of 2024.

Avidity Biosciences has successfully raised approximately $400 million through an oversubscribed private placement to fund its clinical-stage product development and extend its operational runway into late 2026.

Avidity Biosciences announces its fourth quarter and year-end 2023 financial results, highlighting progress in clinical programs and a strong cash position.